Navigation Links
NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference
Date:2/5/2010

ROCKVILLE, Md., Feb. 5 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the 12th Annual BIO CEO & Investor Conference on February 8th, 2010 at 10:00 am local time. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf=Astoria, New York.  Dr. Singhvi will provide an overview of the company's business strategy, research and development progress and upcoming milestones.  A link to the live audio only presentation can be accessed via the Company website at www.novavax.com under the Investors tab.  An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology.  The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches.  Novavax is committed to using its VLP technology to create country-specific vaccine solutions.  The company has formed a joint ve
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... newly developed Bruton,s tyrosine kinase (BTK) inhibitor for ... results of these preclinical evaluations have been communicated ... feedback received from the Agency is supportive of ... preclinical work is required to begin a Phase ...
(Date:2/27/2015)... The fully automated supercritical fluidic chromatography-based ... analyze up to 48 samples utilizing automatic extraction ... targets by mass spectrometry. , The Nexera ... requirements of a wide range of applications, including ... search for disease biomarkers, additives in forming polymers, ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... WOODBRIDGE, N.J. , Feb. 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... a trade secrets lawsuit against Genewiz Inc. in excess ... obtained and utilized GenScript,s trade secrets, and that it ... court entered an order denying motions for judgment notwithstanding ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... KENILWORTH, N.J., Oct. 11 Schering-Plough,Corporation (NYSE: ... approval from,the European Commission for its planned acquisition ... announced March 12. Organon BioSciences is comprised ... the animal health business. It also,includes Nobilon, the ...
... Calif., Oct. 11 AMDL, Inc. (Amex:,ADL), ... Shenzhen,Jiangxi and Jilin, China, through its wholly ... international biopharma company that,engages in the development, ... products. AMDL announced today that JPI has,signed ...
... vascular tissue processing revenues in the third, quarter of 2007 increased ... ... ATLANTA, Oct. 11 CryoLife, Inc. (NYSE: CRY ),a ... preservation services revenues for the third quarter,of 2007 were approximately $21.9 ...
Cached Biology Technology:Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V. 2AMDL Expands Drug Distribution in China With Additional Agreement, Valued at $2.3 Million Annually 2CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 2CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 3CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 4CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 5
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... hosts a panel discussion and open public forum about ... for Biosecurity (NSABB), which advises the U.S. Department of ... journals that they redact key information from unpublished manuscripts ... both good and bad purposes. The research in ...
... 10, 2012  Trovagene, Inc. (Pink Sheets: TROV.PK), a ... Stephen Zaniboni has been named Chief Financial Officer. ... more than $500 million through venture financing and ... of healthcare software solutions company Awarepoint and XIFIN ...
... today that it will receive a tuberculosis (TB) biomarkers ... Challenges in Global Health program, an initiative that seeks ... can radically improve health in the developing world. Urs ... SomaLogic, will pursue an innovative research project to identify ...
Cached Biology News:Georgetown hosts forum to discuss government request of journals to redact scientific data 2Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer 2Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer 3SomaLogic Inc. receives Grand Challenges tuberculosis biomarkers grant 2
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Biology Products: